Julie 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics en GenScript ProBio is besig om 'n kontrak te onderteken vir die ontwikkeling en produksie van plasmied- en virusvektore vir die eerste pyplyn van ACT Therapeutics se Advanced CAR-T Platform (ACT-platform), wat ook opdrag gegee sal word om grondstowwe te vervaardig. vir ACT Therapeutics se daaropvolgende pypleidings. Die kontrak sal die produksie van plasmiede en virusvektore vir die eerste pyplyn van ACT Therapeutics se Advanced CAR-T-platform dek.
As gevolg van hierdie ooreenkoms is GenScript ProBio verhef tot die status van 'n globale vennoot wat in staat is om ACT-platforms vir ACT-terapeutika te ondersteun.
Die ACT-platform is 'n volgende generasie sel- en geenterapie-tegnologie wat kankerantigene teiken deur gene wat ontwerp is om daardie antigene in immuunselle te teiken, in te voeg. Hierdie gene word in immuunselle afgelewer deur die gebruik van virusvektore. GenScript ProBio beskik oor 'n hoëgehalte virusvektorprosesontwikkeling en 'n eenstopdiensplatform vir GMP-produksie, wat albei nodig is vir die ontwikkeling van sel- en geenterapie.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing bloedkanker. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, HUB van GenScript ProBio, het gesê: "Ons is baie bly om saam te werk met ACT therapeutics in strategiese vennootskap, en ons sien daarna uit om ACT Therapeutics se ACT-platform as 'n globale vennoot te ondersteun deur ons opgehoopte tegnologie."
Seogkyoung-Kong, HUB van ACT Therapeutics, het gesê: “Ons het voorbereidings vir die ACT-platform voltooi om wêreldwyd na vore te kom deur 'n strategiese vennootskap met GenScript ProBio. Ons sal die ontwikkeling van behandelings wat gerig is op vuurvaste en onoplosbare soliede kankers versnel.”
Oor GenScript ProBio
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
In die rigting van die missie van "Innovasie deur samewerking", is GenScript ProBio daartoe verbind om kliënte te help om die tydlyn vir die ontwikkeling van biologiese middels van ontdekking tot kommersialisering te verkort, wat R&D-koste aansienlik verlaag en 'n gesonder toekoms bou.
